ライフサイエンスコーパス: beta-antagonist

1 to HCMV infection, identifying IE2 as an IFN-beta antagonist.

2 exposure and were also inhibited by PKCalpha/beta antagonist.

3 with carvedilol and metoprolol, a selective beta-antagonist.

4 tions as an alpha/beta interferon (IFN-alpha/beta) antagonist.

5 could the synergism be blocked by alpha1- or beta-antagonists.

6 nced (P < 0.01) by propranolol (nonselective beta antagonist; -53 +/- 6%), CGP-20,712A (selective bet

7 where classic agonists (catecholamines) and beta-antagonists act, and 2) where CGP 12177 is an agoni

8 eplaced by alanine residues, do not have TGF-beta antagonist activity.

9 A short-acting beta-antagonist administered immediately after defibrill

10 nd is also found in neurite plaques, the TGF-beta antagonist and partial agonist activities of Abeta

11 ovide insights into developing effective TGF-beta antagonists and biomarkers for patient selection an

12 ers and Abeta aggregates may function as TGF-beta antagonists and partial agonists, analogous to prev

13 ells, and this activation was prevented by a beta-antagonist and by protein kinase A inhibitors but n

14 adrenergic agents propranolol (non-selective beta-antagonist) and salbutamol (beta(2)-agonist), which

15 t-derived growth factor receptor-beta (PDGFr-beta) antagonist, and the tumor-seeking radiolabeled ant

16 rus-encoded alpha/beta interferon (IFN-alpha/beta) antagonist, appears to be a key regulator of prote

17 f prostaglandin analogs, which are replacing beta-antagonists as the drug of first choice.

18 virus is an alpha/beta interferon (IFN-alpha/beta) antagonist, both in vitro and in experimental anim

19 tions as an interferon alpha/beta (IFN-alpha/beta) antagonist by preventing the synthesis of IFN duri

20 de evidence that therapeutic dosing of a TGF-beta antagonist can diminish and potentially reverse hep

21 viously shown that high molecular weight TGF-beta antagonists can suppress metastasis without the pre

22 We hypothesized that the nonselective beta-antagonist carvedilol, through its alpha1-adrenergi

23 gated whether microiontophoretic ejection of beta antagonists could inhibit thalamocortical activity

24 pothesis that the transforming growth factor-beta antagonist decorin has therapeutic potential for re

25 However, many beta antagonists do stimulate very small beta(2) adrenoc

26 hat the ability of BF-1 to function as a TGF-beta antagonist does not require its DNA binding activit

27 n, and reperfusion and that the short-acting beta-antagonist esmolol administered at reperfusion woul

28 ividual components of an investigational non-beta-antagonist fixed combination of brinzolamide, 1%, a

29 ify the transforming growth factor beta (TGF-beta) antagonist follistatin (Fst) as a key mediator of

30 Thus this soluble TGF-beta antagonist has potential for long-term clinical use

31 Several compounds described previously as beta-antagonists have agonist properties at the beta3-ad

32 that can be mitigated by treatment with TGF-beta antagonists, including angiotensin II-receptor bloc

33 raventricular administration of propranolol (beta antagonist) initiated a significant increase in pro

34 The Dan family of transforming growth factor beta antagonists is a large, evolutionarily conserved fa

35 A specific PKCalpha/beta antagonist (myristoylated PKCalpha/beta peptide) bl

36 In the presence of a beta antagonist, NE induced an inward current that rever

37 ed TGF-beta genes Nv-dpp, Nv-BMP5-8, six TGF-beta antagonists (NvChordin, NvNoggin1, NvNoggin2, NvGre

38 e developed transgenic mice expressing a TGF-beta antagonist of the soluble type II TGF-beta receptor

39 IL-1 beta antagonists or proteasome inhibitors might increase

40 ment of rats with TbetaRII/Fc chimera, a TGF-beta antagonist, or U0126, a specific MEK inhibitor, cou

41 eta agonist isoproterenol and blocked by the beta antagonist propranolol.

42 , and treatment of stressed animals with the beta-antagonist propranolol reversed the stress-induced

43 beta-antagonist (propranolol) suppressed subchondral bon

44 The alpha2 antagonist idazoxan and the beta antagonist propranolole, however, failed to prevent

45 emia in P. falciparum cultures in vitro, and beta-antagonists reduced parasitemia of P. berghei infec

46 cantly ameliorated by treatment with the TGF-beta antagonist soluble TGFbetaR-Fc (sTGFbetaR-Fc).

47 F-beta signaling and can be prevented by TGF-beta antagonists such as TGF-beta-neutralizing antibody

48 Synthetic TGF-beta antagonists therefore could have therapeutic utilit

49 ral, but not unilateral, MS infusions of the beta-antagonist timolol (3.75 microg, 8.7 nmol) decrease

50 rs for patient selection and efficacy of TGF-beta antagonist treatment.